TY - JOUR
T1 - Genome-Wide Association Study of Age-Related Macular Degeneration Reveals 2 New Loci Implying Shared Genetic Components with Central Serous Chorioretinopathy
AU - Akiyama, Masato
AU - Miyake, Masahiro
AU - Momozawa, Yukihide
AU - Arakawa, Satoshi
AU - Maruyama-Inoue, Maiko
AU - Endo, Mikiko
AU - Iwasaki, Yusuke
AU - Ishigaki, Kazuyoshi
AU - Matoba, Nana
AU - Okada, Yukinori
AU - Yasuda, Miho
AU - Oshima, Yuji
AU - Yoshida, Shigeo
AU - Nakao, Shin ya
AU - Morino, Kazuya
AU - Mori, Yuki
AU - Kido, Ai
AU - Kato, Aki
AU - Yasukawa, Tsutomu
AU - Obata, Ryo
AU - Nagai, Yoshimi
AU - Takahashi, Kanji
AU - Fujisawa, Kimihiko
AU - Miki, Akiko
AU - Nakamura, Makoto
AU - Honda, Shigeru
AU - Ushida, Hiroaki
AU - Yasuma, Tetsuhiro
AU - Nishiguchi, Koji M.
AU - Mori, Ryusaburo
AU - Tanaka, Koji
AU - Wakatsuki, Yu
AU - Yamashiro, Kenji
AU - Kadonosono, Kazuaki
AU - Terao, Chikashi
AU - Ishibashi, Tatsuro
AU - Tsujikawa, Akitaka
AU - Sonoda, Koh Hei
AU - Kubo, Michiaki
AU - Kamatani, Yoichiro
N1 - Funding Information:
This study used the data obtained from the BioBank Japan Project supported by the Ministry of Education, Culture, Sports, Sciences and Technology of the Japanese government and the Japan Agency for Medical Research and Development (AMED; grant nos.: JP20km0605001 and JP17km0305002). Supported by Japan Society for the Promotion of Science (JSPS) KAKENHI (grant nos.: 20H03841 [M.M.] and 22H00476 [Y.O.]); the Ministry of Education, Culture, Sports, Sciences and Technology (Grant-in-Aid for Scientific Research no.: 19K09997 [S.H.]); and AMED (grant nos.: JP21gm4010006, JP22km0405211, JP22ek0410075, JP22km0405217, and JP22ek0109594 [Y.O.]).
Publisher Copyright:
© 2022 American Academy of Ophthalmology
PY - 2022
Y1 - 2022
N2 - Purpose: To investigate the genetic architecture of age-related macular degeneration (AMD) in a Japanese population. Design: Genome-wide association study (GWAS). Participants: Three thousand seven hundred seventy-two patients with AMD and 16 770 control participants from the Japanese population were enrolled in the association analyses. Methods: We conducted a meta-analysis of 2 independent GWASs that included a total of 2663 patients with AMD and 9471 control participants using the imputation reference panel for genotype imputation specified for the Japanese population (n = 3541). A replication study was performed using an independent set of 1109 patients with AMD and 7299 control participants. Main Outcome Measures: Associations of genetic variants with AMD. Results: A meta-analysis of the 2 GWASs identified 6 loci significantly associated with AMD (P < 5.0 × 10–8). Of these loci, 4 were known to be associated with AMD (CFH, C2/FB, TNFRSF10A, and ARMS2), and 2 were novel (rs4147157 near WBP1L and rs76228488 near GATA5). The newly identified associations were confirmed in a replication study (P < 0.01). After the meta-analysis of all datasets, we observed strong associations in these loci (P = 1.88 × 10–12 and P = 1.35 × 10–9 for meta-analysis for rs4147157 and rs76228488, respectively). When we looked up the associations in the reported central serous chorioretinopathy (CSC) GWAS conducted in the Japanese population, both loci were associated significantly with CSC (P = 4.86 × 10–3 and P = 4.28 × 10–3 for rs4147157 and rs76228488, respectively). We performed a genetic colocalization analysis for these loci and estimated that the posterior probabilities of shared causal variants between AMD and CSC were 0.39 and 0.60 for WBP1L and GATA5, respectively. Genetic correlation analysis focusing on the epidemiologically suggested clinical risk factors implicated shared polygenic architecture between AMD and smoking cessation (rg [the measure of genetic correlation] = –0.33; P = 0.01; false discovery rate, 0.099). Conclusions: Our findings imply shared genetic components conferring the risk of both AMD and CSC. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.
AB - Purpose: To investigate the genetic architecture of age-related macular degeneration (AMD) in a Japanese population. Design: Genome-wide association study (GWAS). Participants: Three thousand seven hundred seventy-two patients with AMD and 16 770 control participants from the Japanese population were enrolled in the association analyses. Methods: We conducted a meta-analysis of 2 independent GWASs that included a total of 2663 patients with AMD and 9471 control participants using the imputation reference panel for genotype imputation specified for the Japanese population (n = 3541). A replication study was performed using an independent set of 1109 patients with AMD and 7299 control participants. Main Outcome Measures: Associations of genetic variants with AMD. Results: A meta-analysis of the 2 GWASs identified 6 loci significantly associated with AMD (P < 5.0 × 10–8). Of these loci, 4 were known to be associated with AMD (CFH, C2/FB, TNFRSF10A, and ARMS2), and 2 were novel (rs4147157 near WBP1L and rs76228488 near GATA5). The newly identified associations were confirmed in a replication study (P < 0.01). After the meta-analysis of all datasets, we observed strong associations in these loci (P = 1.88 × 10–12 and P = 1.35 × 10–9 for meta-analysis for rs4147157 and rs76228488, respectively). When we looked up the associations in the reported central serous chorioretinopathy (CSC) GWAS conducted in the Japanese population, both loci were associated significantly with CSC (P = 4.86 × 10–3 and P = 4.28 × 10–3 for rs4147157 and rs76228488, respectively). We performed a genetic colocalization analysis for these loci and estimated that the posterior probabilities of shared causal variants between AMD and CSC were 0.39 and 0.60 for WBP1L and GATA5, respectively. Genetic correlation analysis focusing on the epidemiologically suggested clinical risk factors implicated shared polygenic architecture between AMD and smoking cessation (rg [the measure of genetic correlation] = –0.33; P = 0.01; false discovery rate, 0.099). Conclusions: Our findings imply shared genetic components conferring the risk of both AMD and CSC. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.
UR - http://www.scopus.com/inward/record.url?scp=85145239236&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145239236&partnerID=8YFLogxK
U2 - 10.1016/j.ophtha.2022.10.034
DO - 10.1016/j.ophtha.2022.10.034
M3 - Article
C2 - 36423732
AN - SCOPUS:85145239236
SN - 0161-6420
JO - Ophthalmology
JF - Ophthalmology
ER -